The company, which has received tremendous support from its shareholders, expects to make further progress in the current year as it looks to broaden the reach of its platforms.

Scancell Holdings PLC (LON:SCLP) said it made strong progress as a business in the year to the end of April, 2020. The developer of immunotherapies for the treatment of cancer and infectious disease revealed in its full-year results that it ended the reporting period with £3.58mln cash, down from £4.56mln at the end of April 2019.

Click here to read the full article.

GET IN TOUCH!


  MAIL US
enquiries@growthinvest.com

  CALL US
020 7071 3945

FOLLOW US ON


Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.